Pharmaco-economic issues for diabetes therapy

2005 Weinstein, 2003, Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices – modeling Studies, Value in Health, 6, 9, 10.1046/j.1524-4733.2003.00234.x 2004, Guidelines for computer modeling of diabetes and its complications. American Diabetes Association Consensus Panel, Diabetes Care, 27, 2262, 10.2337/diacare.27.9.2262 Wild, 2004, Global prevalence of diabetes estimates for the year 2000 and projections for 2030, Diabetes Care, 27, 1047, 10.2337/diacare.27.5.1047 Centers for Disease Control and Prevention. National Diabetes Surveillance System. Prevalence of Diabetes. Accessed 9 June 2007, at http://www.cdc.gov/diabetes/statistics/prev/national/tnumage.htm. Centers for Disease Control and Prevention, 2005 The task force on diabetes and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes and cardiovascular diseases: Full text. www.escardio.org and www.easd.org Accessed May 2007. 2006 Finkelstein, 2007, Age-specific impact of obesity on prevalence and costs of diabetes and dyslipidemia, Value in Health, 10, S45, 10.1111/j.1524-4733.2006.00154.x Dr Foster's case notes, 2005, Obesity and type-2 diabetes in children, 1996-7 to 2003-4, BMJ, 331, 1167, 10.1136/bmj.331.7526.1167 Pinhas-Hamiel, 2005, The global spread of type-2 diabetes mellitus in children and adolescents, The Journal of Pediatrics, 146, 693, 10.1016/j.jpeds.2004.12.042 Caro, 2007, Economic burden and risk of cardiovascular disease and diabetes in patients with different cardiometabolic risk profiles, Value in Health, 10, S12, 10.1111/j.1524-4733.2006.00150.x Roper, 2001, Excess mortality in a population with diabetes and the impact of material deprivation: longitudinal, population based study, BMJ, 322, 1389, 10.1136/bmj.322.7299.1389 Almdal, 2004, The independent effect of type-2 diabetes mellitus on ischaemic heart disease, stroke and death: a population-based study of 13,000 men and women with 20 years of follow-up, Archives of Internal Medicine, 164, 1422, 10.1001/archinte.164.13.1422 Fisher, 2001, Diabetes: a state of premature cardiovascular death, Practical Diabetes International, 18, 183, 10.1002/pdi.243 American Diabetes Association. Complications of diabetes in the United States. Accessed 12 June 2007, at http://www.diabetes.org/diabetes-statistics/complications.jsp Koopmanschap, 2002, Coping with type-II diabetes: the patient's perspective, Diabetologia, 45, S18, 10.1007/s00125-002-0861-2 Bagust, 2005, Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data, Health Economics, 14, 217, 10.1002/hec.910 Clarke, 2002, Estimating utility values for health states of type-2 diabetic patients using the EQ-5D UKPDS 62, Medical Decision Making, 22, 340, 10.1177/027298902400448902 Coffey, 2002, Valuing health-related quality of life in diabetes, Diabetes Care, 25, 2238, 10.2337/diacare.25.12.2238 Jönsson, 2002, Revealing the cost of Type-II diabetes in Europe, Diabetologia, 45, S5, 10.1007/s00125-002-0858-x Williams, 2001, CODE-2*UK: Our contribution to a European Study of the costs of Type-2 diabetes, Practical Diabetes International, 18, 235, 10.1002/pdi.238 Currie, 1997, Patterns and costs of hospital care for coronary heart disease related and not related to diabetes, Heart, 78, 544, 10.1136/hrt.78.6.544 Bagust, 2001, An economic model of the long-term health care burden of Type-II diabetes, Diabetologia, 44, 2140, 10.1007/s001250100023 Bagust, 2002, The projected health care burden of Type-2 diabetes in the UK from 2000 to 2060, Diabetic Medicine, 19, 1, 10.1046/j.1464-5491.19.s4.2.x Caro, 2002, Lifetime costs of complications resulting from type-2 diabetes in the US, Diabetes Care, 25, 476, 10.2337/diacare.25.3.476 Raikou, 2003, The economics of screening and treatment in type-2 diabetes mellitus, Pharmaco-economics, 21, 543, 10.2165/00019053-200321080-00002 National Diabetes Data Group, 1995 Williams, 2002, Assessing the impact of complications on the costs of type-II diabetes, Diabetologia, 45, S13, 10.1007/s00125-002-0859-9 Bottomley JM on behalf of the TARDIS Steering Committee and UK Centres, 2001, Managing care of type-2 diabetes. Learnings from T2ARDIS, British Journal of Diabetes and Vascular Disease, 1, 68, 10.1177/14746514010010011201 Evans, 2000, Impact of type-1 and type-2 diabetes on patterns and costs of drug prescribing: a population-based study, Diabetes Care, 23, 770, 10.2337/diacare.23.6.770 Holmes, 2003, Do people with type-2 diabetes and their carers lose income? (T2ARDIS-4), Health Policy, 64, 291, 10.1016/S0168-8510(02)00177-X Sullivan, 2007, Cardiovascular risk factor clusters and employment in the United States, Value in Health, 10, S52, 10.1111/j.1524-4733.2006.00155.x Day, 2007, Diabetes. A new world order?, British Journal of Diabetes and Vascular Disease, 7, 3, 10.1177/14746514070070010101 2003, Economic costs of diabetes in the US in 2002. American Diabetes Association, Diabetes Care, 26, 917, 10.2337/diacare.26.3.917 Gray, 1995, The cost of insulin-dependent diabetes mellitus (IDDM) in England and Wales, Diabet Medicine, 12, 1068, 10.1111/j.1464-5491.1995.tb00423.x Henriksson, 1998, Diabetes: the cost of illness in Sweden, Journal of Internal Medicine, 244, 461, 10.1111/j.1365-2796.1998.00388.x Brouwer, 2006, Too important to ignore. Informal caregivers and other significant others, Pharmacoeconomics, 24, 39, 10.2165/00019053-200624010-00003 The UK Prospective Diabetes Study Group, 1998, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type-2 diabetes (UKPDS 33), Lancet, 352, 837, 10.1016/S0140-6736(98)07019-6 The UK Prospective Diabetes Study Group, 1998, Effect of intensive blood glucose control with metformin on complications in overweight patients with type-2 diabetes: UKPDS 34, Lancet, 352, 854, 10.1016/S0140-6736(98)07037-8 Gaede, 2003, Multifactorial intervention and cardiovascular disease in patients with type-2 diabetes, The New England Journal of Medicine, 348, 383, 10.1056/NEJMoa021778 UK Prospective Diabetes Study (UKPDS) Group, 1998, Tight blood pressure control and risk of macrovascular and microvascular complications in type-2 diabetes. (UKPDS 38), BMJ, 317, 703, 10.1136/bmj.317.7160.703 Colhoun, 2004, Primary prevention of cardiovascular disease with atorvastatin in type-2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial, Lancet, 364, 685, 10.1016/S0140-6736(04)16895-5 The FIELD study investigators, 2005, Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type-2 diabetes mellitus (the FIELD study): randomised controlled trial, Lancet, 366, 1849, 10.1016/S0140-6736(05)67667-2 Hansson, 1998, Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: principle results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group, Lancet, 351, 1755, 10.1016/S0140-6736(98)04311-6 Pyorala, 1997, Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S), Diabetes Care, 20, 614, 10.2337/diacare.20.4.614 Rubins, 1999, Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol, The New England Journal of Medicine, 341, 410, 10.1056/NEJM199908053410604 Heart Outcomes Prevention Evaluation (HOPE) Study Investigators, 2000, Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE and MICRO-HOPE substudy, Lancet, 355, 253, 10.1016/S0140-6736(99)12323-7 Heart Protection Study Collaborative Group, 2003, MRC/BHF Heart protection Study of cholesterol-lowering with simvastatin in 5953 people with diabetes: a randomised placebo-controlled trial, Lancet, 361, 2005, 10.1016/S0140-6736(03)13636-7 Dormandy, 2005, Secondary prevention of macrovascular events in patients with type-2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial, Lancet, 366, 1279, 10.1016/S0140-6736(05)67528-9 Gray, 2000, Cost effectiveness of an intensive blood glucose control policy in patients with type-2 diabetes: economic analysis alongside randomised controlled trial. UKPDS Group 41, BMJ, 320, 1373, 10.1136/bmj.320.7246.1373 UK Prospective Diabetes Study (UKPDS) Group, 1998, Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type-2 diabetes. UKPDS 40, BMJ, 317, 720, 10.1136/bmj.317.7160.720 Clarke, 2001, Cost effectiveness analysis of intensive blood glucose control with metformin in overweight patients with Type-II diabetes (UKPDS 51), Diabetologia, 44, 298, 10.1007/s001250051617 Clarke, 2005, Cost-utility analyses of intensive blood glucose and tight blood pressure control in type-2 diabetes. UKPDS 72, Diabetologia, 48, 868, 10.1007/s00125-005-1717-3 Nyman, 2002, Cost-effectiveness of gemfibrozil for coronary heart disease patients with low levels of high-density lipoprotein cholesterol, Archives of Internal Medicine, 162, 177, 10.1001/archinte.162.2.177 Schädlich, 2004, Cost effectiveness of Ramipril in patients at high risk for cardiovascular events. Economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) Study for Germany from the Statutory Health Insurance Perspective, Pharmacoeconomics, 22, 955, 10.2165/00019053-200422150-00001 Grover, 2001, How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease?, Diabetes Care, 24, 45, 10.2337/diacare.24.1.45 Jönsson, 1999, The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial, Diabetologia, 42, 1293, 10.1007/s001250051441 Brändle, 2003, Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type-2 diabetes, Diabetes Care, 26, 1796, 10.2337/diacare.26.6.1796 Jönsson, 2003, Health economics in the Hypertension Optimal Treatment (HOT) study: costs and cost-effectiveness of intensive blood pressure lowering and low-dose aspirin in patients with hypertension, Journal of Internal Medicine, 253, 472, 10.1046/j.1365-2796.2003.01135.x Valentine, 2007, PROactive 06: Cost effectiveness of pioglitazone in type-2 diabetes in the UK, Diabetic Medicine, 10.1111/j.1464-5491.2007.02188.x Tilden, 2007, A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type-2 diabetes in the UK, Pharmacoeconomics, 25, 39, 10.2165/00019053-200725010-00005 Beale, 2006, Cost-effectiveness of rosiglitazone combination therapy for the treatment of type-2 diabetes mellitus in the UK, Pharmacoeconomics, 24, 21, 10.2165/00019053-200624001-00003 Raikou, 2007, Cost effectiveness of primary prevention of cardiovascular disease with atorvastatin in type-2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS), Diabetologia, 50, 733, 10.1007/s00125-006-0561-4 Mihaylova, 2005, Heart Protection Study Collaboartive Group. Cost effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomized trial in 20,536 individuals, Lancet, 356, 1779 1999, UKPDS 37. Quality of life in Type-2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control. UKPDS Study Group, Diabetes Care, 22, 1125, 10.2337/diacare.22.7.1125 The DCCT Research Group, 1993, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus, The New England Journal of Medicine, 329, 977, 10.1056/NEJM199309303291401 The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications research Group, 2000, Retinopathy and nephropathy in patients with type-1 diabetes four years after trial of intensive therapy, The New England Journal of Medicine, 342, 381, 10.1056/NEJM200002103420603 Palmer, 2004, The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making, Current Medical Research and Opinion, 20, S5, 10.1185/030079904X1980 The Diabetes Control and Complications Trial Research Group, 1996, Lifetime benefits and and costs of intensive therapy as practiced in the diabetes control and complications trial, JAMA, 276, 1409, 10.1001/jama.276.17.1409 The DREAM trial investigators, 2006, Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial, Lancet, 368, 1096, 10.1016/S0140-6736(06)69420-8 Diabetes Prevention Program Research Group, 2005, Prevention of type-2 diabetes with troglitazone in the Diabetes Prevention Program, Diabetes, 54, 1150, 10.2337/diabetes.54.4.1150 Tuomilehto, 2001, Prevention of type-2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. Finnish Diabetes Prevention Study, The New England Journal of Medicine, 344, 1343, 10.1056/NEJM200105033441801 Chiasson, 2002, Acarbose for prevention of type-2 diabetes mellitus: the STOP-NIDDM randomised trial, Lancet, 359, 2072, 10.1016/S0140-6736(02)08905-5 The Diabetes Prevention Program Research Group, 2002, Reduction in the incidence of type-2 diabetes with lifestyle intervention or metformin, The New England Journal of Medicine, 346, 393, 10.1056/NEJMoa012512 Xiang, 2006, Effect of pioglitazone on pancreatic beta cell function and diabetes risk in Hispanic women with prior gestational diabetes, Diabetes, 55, 517, 10.2337/diabetes.55.02.06.db05-1066 Ramachandran, 2006, The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type-2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1), Diabetologia, 49, 289, 10.1007/s00125-005-0097-z Kahn, 2006, Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy, The New England Journal of Medicine, 355, 2427, 10.1056/NEJMoa066224 The Diabetes Prevention Program Research Group, 2003, Costs associated with the primary prevention of type-2 diabetes in the DPP, Diabetes Care, 26, 36, 10.2337/diacare.26.1.36 Palmer, 2004, Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: modeling the long-term health economic implications of the DPP in Australia, France, Switzerland and the United Kingdom, Clinical Therapeutics, 26, 304, 10.1016/S0149-2918(04)90029-X Herman, 2005, The cost effectiveness of lifestyle modification or metformin in preventing type-2 diabetes in adults with impaired glucose tolerance, Annals of Internal Medicine, 142, 323, 10.7326/0003-4819-142-5-200503010-00007 Eddy, 2005, Clinical outcomes and cost effectiveness of strategies for managing people at high risk for diabetes, Annals of Internal Medicine, 143, 251, 10.7326/0003-4819-143-4-200508160-00006 Caro, 2004, Economic evaluation of therapeutic interventions to prevent type-2 diabetes in Canada, Diabetes Medicine, 21, 1229, 10.1111/j.1464-5491.2004.01330.x Klonoff, 2000, An economic analysis of interventions for diabetes, Diabetes Care, 23, 390, 10.2337/diacare.23.3.390 Zhang, 2004, Application of economic analysis to diabetes and diabetes care, Annals of Internal Medicine, 140, 972, 10.7326/0003-4819-140-11-200406010-00039 Vijgen, 2006, Cost effectiveness of preventative interventions in type-2 diabetes mellitus. A systematic literature review, Pharmacoeconomics, 24, 425, 10.2165/00019053-200624050-00002 Waugh, 2007, Screening for type-2 diabetes: literature review and economic modeling, Health Technology Assessment, 11, 10.3310/hta11170 Icks, 2007, Clinical and cost effectiveness of primary prevention of type-2 diabetes in a ‘real world’ routine healthcare setting: model based on the KORA Survey 2000, Diabetes Medicine, 24, 473, 10.1111/j.1464-5491.2007.02108.x Nathan, 2006, Management of hyperglycaemia in type-2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes, Diabetes Care, 29, 1963, 10.2337/dc06-9912 Calvert, 2007, Management of type-2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort study, British Journal of General Practice, 57, 455 Fox, 2006, Prevalence of inadequate glycaemic control among patients with type-2 diabetes in the United Kingdom General Practice Research Database: a series of retrospective analyses of data from 1998 through 2002, Clinical Therapy, 28, 388, 10.1016/j.clinthera.2006.03.005 Liebl, 2002, Evaluation of risk factors for development of complications in type-II diabetes in Europe, Diabetologia, 45, S23, 10.1007/s00125-002-0863-0 Barnett, 2004, Treating to goal. Challenges of current management, European Journal of Endocrinology, 151, T3, 10.1530/eje.0.151T003 Cook, 2005, Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type-2 diabetes, Diabetes Care, 28, 995, 10.2337/diacare.28.5.995 Chuang, 2002, The status of diabetes control in Asia – a cross-sectional survey of 24,317 patients with diabetes mellitus in 1998, Diabetes Medicine, 19, 978, 10.1046/j.1464-5491.2002.00833.x O'Hare, 2004, Evaluation of delivery of enhanced diabetes care to patients of South Asian ethnicity: The United Kingdom Asian Diabetes Study (UKADS), Diabetes Medicine, 21, 1357, 10.1111/j.1464-5491.2004.01373.x Riddle, 2005, Glycemic management of type-2 diabetes: an emerging strategy with oral agents, insulins, and combinations, Endocrinology and Metabolism Clinics of North America, 34, 77, 10.1016/j.ecl.2004.12.002 Krentz, 2005, Oral antidiabetic agents. Current role in type-2 diabetes mellitus, Drugs, 65, 385, 10.2165/00003495-200565030-00005 Nathan, 2007, Finding new treatments for diabetes – how many, how fast….how good?, The New England Journal of Medicine, 356, 437, 10.1056/NEJMp068294 Cohen, 2007, Progress in the treatment of type-2 diabetes: new pharmacologic approaches to improve glycemic control, Current Medical Research and Opinion, 23, 905, 10.1185/030079907X182068 Palmer, 2004, Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type-1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials, Current Medical Research and Opinion, 20, 1729, 10.1185/030079904X5661 Minshall, 2003, Long-term cost-effectiveness of insulin aspart versus soluble human insulin in patients with type-1 diabetes in the United Kingdom, Value in Health, 8, 358, 10.1016/S1098-3015(10)62955-5 McEwan, 2007, Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type-1 diabetes in the UK, Current Medical Research and Opinion, 23, S7, 10.1185/030079907X167561 McEwan, 2007, Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type-2 diabetes in the UK, Current Medical Research and Opinion, 23, S21, 10.1185/030079907X167570 Palmer, 2007, An economic assessment of analgue basal-bolus insulin versus human basal-bolus insulin in subjects with type-1 diabetes in the UK, Current Medical Research and Opinion, 23, 895, 10.1185/030079907X182194 Hermansen, 2004, Insulin analogues (insulin determir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type-1 diabetes, Diabetologia, 47, 622, 10.1007/s00125-004-1365-z Mueller, 2006, Development and validation of the Economic Assessment of Glycaemic control and Long-term Effects of diabetes (EAGLE) Model, Diabetes Technology and Therapeutics, 8, 219, 10.1089/dia.2006.8.219 Devlin, 2004, Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis, Health Economics, 13, 437, 10.1002/hec.864 Plun-Favreau, 2006, Cost-effectiveness of inhaled insulin in patients with diabetes uncontrolled on their current therapy: the UK base case submitted to the National Institute for Health and Clinical Excellence, Value in Health, 9, A235, 10.1016/S1098-3015(10)63305-0 Neovius, 2006, The cost effectiveness of inhaled insulin in Sweden, Value in Health, 9, A231, 10.1016/S1098-3015(10)63293-7 Cvetković, 2007, Exenetide. A review of its use in patients with type-2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea), Drugs, 67, 935 Palmer, 2004, Validation of the CORE Diabetes Model against Epidemiological and Clinical Studies, Current Medical Research and Opinion, 20, S27, 10.1185/030079904X2006 Watkins, 2006, Application of economic analyses in US managed care formulary decisions: a private payer's experience, Journal of Managed Care Pharmacy, 12, 726, 10.18553/jmcp.2006.12.9.726 Ray, 2007, Exenatide versus insulin glargine in patients with type-2 diabetes in the UK: a model of long-term clinical and cost outcomes, Current Medical Research and Opinion, 23, 609, 10.1185/030079907X178685 Edwards, 2006, Cost effectiveness of intermediate or long-acting insulin versus Exenatide in type-2 diabetes mellitus patients not optimally controlled on dual oral diabetes medications, Pharmacy Practice, 4, 129 Revicki, 2000, Recommendations on health-related quality of life research to support labelling and promotional claims in the United States, Quality of Life Research, 9, 887, 10.1023/A:1008996223999 Hill, 2003 Warren, 2004, Systematic review of economic evaluation of a long-acting insulin analogue, insulin glargine, Health Technology Assessment, 8, 1, 10.3310/hta8450 2002 Currie, 2006, Multivariate models of health related utility and the fear of hypoglycaemia in people with diabetes, Current Medical Research and Opinion, 22, 1523, 10.1185/030079906X115757 Insulin glargine (Lantus®) Aventis. No. 11/02, 4 October 2002; Insulin detemir (Lememir®). Novo Nordisk No. 110/04, 9 August 2004; Insulin detemir (Lememir®). Novo Nordisk No. 138/04, 5 November 2004. All available at www.scottishmedicines.org Accessed in June 2007. Public Summary Document, Insulin detemir (rys) cartridge 3 mL (Penfill®), prefilled device 3 mL (FlexPen®), 100U/mL, Levemir®, March 2006; Insulin glargine, injection, 100 units per mL, 10 mL vials and 3 mL × 5 cartridges, Lantus®, March 2006. Available at http://www.health.gov.au/internet/wcms/publishing.nsf/Content/pbac-outcomes-and-public-summary-documents Accessed June 2007. NICE technology appraisal guidance 113 Inhaled insulin for the treatment of diabetes (types 1 and 2). Available at www.nice.org.uk Accessed in June 2007. Black See Exenetide, 5 or 10 micrograms, solution for injection, pre-filled pen (Byetta®). Eli Lilly and Company Limited. No. (376/07). Guidance 9 July 2007. Available at www.scottishmedicines.org.uk Nauck, 2007, A comparison of twice daily exenetide and biphasic insulin aspart in patients with type-2 diabetes who are suboptimally controlled with sulphonylurea and metformin: a non-inferiority study, Diabetologia, 50, 259, 10.1007/s00125-006-0510-2 See series of 2007 Press Releases at http://en.sanofi-aventis.com/press/p_press_2007.asp Accessed 3 July 2007. Turner, 1999, Glycemic control with diet, sulfonylurea, metformin or insulin in patients with type-2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group, JAMA, 281, 2005, 10.1001/jama.281.21.2005 National Institute for Clinical Excellence, 2002 Clinical Guideline Diabetes – Type-2 (update). Type-2 diabetes: the management of type-2 diabetes (update). National Institute for Health and Clinical Excellence, London. Available at http://guidance.nice.org.uk/page.aspx?o=264875. Accessed June 2007. Drug Trend Report, 2007. Medco Health Solutions, Inc. Report available at www.drugtrend.com or www.medco.com. Harbour, 2001, A new system for grading recommendations in evidence based guidelines, BMJ, 323, 334, 10.1136/bmj.323.7308.334 NICE, 2006 Rothwell, 2005, External validity of randomized controlled trials: ‘To whom do the results of this trial apply?’, Lancet, 365, 82, 10.1016/S0140-6736(04)17670-8 Peterson, 2006, Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir, Current Medical Research and Opinion, 22, 2613, 10.1185/030079906X154178 Currie, 2007, The outcome of care in people with type-1 and type-2 diabetes following switching to treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis, Current Medical Research and Opinion, 23, S33, 10.1185/030079907X167534 Poole, 2007, The prescription cost of managing people with type-1 and type-2 diabetes following initiation of treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis, Current Medical Research and Opinion, 23, S41, 10.1185/030079907X167589 Bottomley, 2006, PROactive03: Pioglitazone, type-2 diabetes and reducing macrovascular events – economic implications?, British Journal of Diabetes and Vascular Disease, 6, 63, 10.1177/14746514060060020401 McCallum, 2006, Comparing cardiovascular outcomes in diabetes studies, British Journal of Diabetes and Vascular Disease, 6, 111, 10.1177/14746514060060030301 Urdahl, 2006, Assessing generalisability in model-based economic evaluation studies. A structured review in osteoporosis, Phamacoeconomics, 24, 1181, 10.2165/00019053-200624120-00004 Manca, 2006, ‘Lost in translation’. Accounting for between-Country differences in the analysis of multinational cost-effectiveness data, Pharmacoeconomics, 24, 1101, 10.2165/00019053-200624110-00007 Goeree, 2007, Transferability of economic evaluations: approaches and factors to consider when using results from one geographic area for another, Current Medical Research and Opinion, 23, 671, 10.1185/030079906X167327 Sculpher, 2004, Generalisability in economic evaluation studies in health care: a review and case studies, Health Technology Assessment, 8, 1, 10.3310/hta8490 Jack, 2007, NICE urged to adjust drug cost rules, Financial Times Little, 2002, NHS to fund treatment for 10 000 patients with MS, BMJ, 324, 316, 10.1136/bmj.324.7333.316a Bell, 2006, Bias in published cost effectiveness studies: systematic review, BMJ, 332, 699, 10.1136/bmj.38737.607558.80 Guide to the methods of technology appraisal review process and timelines. GuideToTAMethodsReview[1]pdf available at http://www.nice.org.uk/page.aspx?o=423153 accessed 20 June 2007.